Understand total testosterone reference ranges, repeat morning testing and how symptoms and SHBG shape a clinician's interpretation.
Total testosterone is the amount of testosterone measured in a blood sample. It is the initial measurement recommended by the Endocrine Society when assessing possible testosterone deficiency. The result is part of a clinical evaluation rather than a diagnosis on its own.
This article is for informational purposes only and is not medical advice. A qualified clinician should assess personal symptoms, interpret test results and make any diagnosis or treatment decision.
The harmonized reference values cited in the Endocrine Society guidance came from healthy, non-obese men aged 19 to 39. They describe a defined reference population rather than a target that every adult man should try to reach.
The reported boundaries were:
These percentiles describe the distribution of measurements in that reference population. They are not boundaries separating every healthy man from every man with hypogonadism. A reference interval helps place a result in context; it does not replace clinical assessment.
Biologically, the result represents testosterone measured in the sampled blood. It is not a direct measurement of symptoms or a score for overall male health. The diagnostic question requires information beyond the concentration itself.
The description of the reference group belongs with the numbers. Removing the age range or the healthy, non-obese criteria makes the interval appear more universal than the evidence supports.
For an individual patient, the relevant discussion includes the laboratory's own interval and the method used to produce the result. The harmonized values provide context, but they should not be substituted automatically for the interpretation attached to every laboratory report.
This is especially important when a result sits near a boundary. The Endocrine Society framework allows clinicians to consider free testosterone when total testosterone is borderline or when sex hormone-binding globulin, known as SHBG, is altered.
A 2026 article in Clinical Chemistry reports that the Endocrine Society's 264 ng/dL lower-limit recommendation came from large cohorts whose measurement methods were standardized through the CDC's Hormone Standardization program.
That history matters because the recommendation is tied to measurement methods and reference data. It should not be presented as though the CDC established an automatic diagnostic threshold for every adult man.
Three questions therefore remain separate:
Testostra's explanation of the context behind a total testosterone measurement provides a broader foundation for understanding those distinctions.
In adult men, the Endocrine Society's diagnostic framework requires symptoms or signs consistent with testosterone deficiency alongside testosterone that is “unequivocally and consistently low.” Neither the symptom history nor the laboratory number is sufficient by itself.
A result below the reference interval does not tell a clinician which symptoms a man has. Those concerns must be discussed rather than inferred from the report. Equally, having symptoms does not establish that testosterone is their cause.
The framework discussed here does not assign a distinct symptom pattern to every below-range or above-range result. Its supported use is to bring clinical findings together with reliable measurements, not to predict how someone should feel from a particular number.
Testing a man because symptoms or clinical circumstances warrant assessment is different from screening a population without symptoms. That distinction affects how a result should be understood.
In its September 2026 statement concerning a Defense Health Agency guideline, the Endocrine Society said evidence was insufficient to support population-level screening of asymptomatic men. It also warned that broad screening could produce false positives.
This is not a recommendation to dismiss symptoms or avoid appropriate testing. It is a warning against turning an isolated screening result into a diagnosis without the required clinical evidence.
For a patient, the useful task is to describe the concerns that prompted testing and ask how they fit the findings. A laboratory flag should not replace that conversation. The same principle applies when someone has symptoms but has not yet had a complete clinical assessment.
The distinction between reporting symptoms and confirming testosterone deficiency helps keep that discussion focused on evaluation rather than self-diagnosis.
The supported factors in this diagnostic approach include collection conditions, measurement reliability and SHBG-related context. These should be distinguished from claims about foods or lifestyle changes that supposedly correct a result.
The Endocrine Society recommends an accurate, reliable fasting morning total testosterone measurement as the initial diagnostic test. It then recommends repeating the morning fasting measurement to confirm a low result.
Morning timing and fasting are therefore part of the recommended collection conditions. A report should be considered alongside information about how the sample was collected, rather than being treated as a number detached from the test process.
The practical discussion is whether the initial measurement followed those conditions and how confirmation should be arranged. The recommendation does not turn fasting into a treatment for low testosterone. It describes how the diagnostic measurement should be obtained.
A first low result establishes that a low value was measured on that occasion. The guideline requires confirmation before that finding becomes part of a diagnosis of consistently low testosterone.
The purpose of repeating the measurement is not simply to generate another number. It is to determine whether the low finding is confirmed within the recommended diagnostic process. Symptoms and signs still remain part of the assessment after that repeat result is available.
The patient should not have to decide independently whether the first result proves a lasting deficiency. That is a clinical judgment based on the combined findings. Understanding why another morning measurement may be needed can make the next appointment more productive.
The guideline framework identifies altered SHBG as a reason to consider free testosterone assessment. A borderline total testosterone result is another situation in which that additional measurement may be relevant.
This does not mean that everyone needs every hormone measurement. It means that total testosterone is the starting test rather than necessarily the complete evaluation. The clinician determines whether another measurement would clarify the particular result.
A useful follow-up question is what uncertainty the additional test is intended to address. Testostra's discussion of borderline results and the role of SHBG gives further context for that conversation.
These diagnostic recommendations do not establish a food, supplement or environmental protocol for changing testosterone. They support a testing and interpretation process rather than a list of interventions for raising a number.
Keeping those purposes separate matters. A requirement for a fasting sample is a collection instruction, while an altered SHBG result is a reason to consider the hormonal context. Neither should be converted into a self-directed hormone treatment plan.
“Does this result fit my symptoms or signs? Was it measured with a reliable morning fasting test and should it be repeated? Which laboratory reference interval applies to me? Could a borderline result or altered SHBG make free testosterone testing useful?”
Sorting out total testosterone and SHBG is a task for the clinician reviewing the report; Testostra makes the language behind that review more accessible. Its evidence-led articles explain related biomarkers and free testosterone so men can distinguish a test result from a diagnostic conclusion, with education kept separate from individual medical decisions.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra